Compare GNLX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNLX | ACOG |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.4M | 193.6M |
| IPO Year | 2022 | 2024 |
| Metric | GNLX | ACOG |
|---|---|---|
| Price | $2.59 | $9.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $17.25 | $16.00 |
| AVG Volume (30 Days) | ★ 297.3K | 162.7K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.47 | ★ 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $10,220,275.00 |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.29 | $4.50 |
| 52 Week High | $8.54 | $10.14 |
| Indicator | GNLX | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 42.41 | 47.79 |
| Support Level | $2.51 | $5.28 |
| Resistance Level | $2.95 | $9.04 |
| Average True Range (ATR) | 0.15 | 0.55 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 25.89 | 3.57 |
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.